Literature DB >> 2127168

A comparative evaluation of iron clearance models.

R J Bergeron1, R R Streiff, J Wiegand, J R Vinson, G Luchetta, K M Evans, H Peter, H B Jenny.   

Abstract

A comparative study of the non-iron-overloaded, bile duct-cannulated rat and of the Cebus monkey as iron-clearance models is presented. The ability of desferrioxamine, desferrithiocin, and a pyridoxal isonicotinoyl hydrazone (PIH) analogue to clear the metal from these two animals is evaluated. Data suggest that although rodents represent a viable first-line animal screen, there is no strict correspondence between the effectiveness of a chelator in rodents and that in primates. Rodent data should be interpreted carefully as it relates to potential human trials. Iron-loading response, the similarity between multiple human and Cebus serum and hematological values, and the ability to easily observe changes in behavioral patterns clearly render the Cebus monkey the best preclinical screen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127168     DOI: 10.1111/j.1749-6632.1990.tb24325.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  16 in total

1.  In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: correlation with physico-chemical properties and oral activity.

Authors:  N Lowther; R Fox; B Faller; H Nick; Y Jin; T Sergejew; Y Hirschberg; R Oberle; H Donnelly
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.

Authors:  Raymond J Bergeron; Neelam Bharti; Jan Wiegand; James S McManis; Shailendra Singh; Khalil A Abboud
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

3.  The design, synthesis, and evaluation of organ-specific iron chelators.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti
Journal:  J Med Chem       Date:  2006-11-30       Impact factor: 7.446

4.  Vibriobactin antibodies: a vaccine strategy.

Authors:  Raymond J Bergeron; Neelam Bharti; Shailendra Singh; James S McManis; Jan Wiegand; Linda G Green
Journal:  J Med Chem       Date:  2009-06-25       Impact factor: 7.446

5.  Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.

Authors:  Anthony Kicic; Anita C G Chua; Erica Baker
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

6.  (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; John R T Vinson; Hua Yao; Neelam Bharti; James R Rocca
Journal:  J Med Chem       Date:  2006-05-04       Impact factor: 7.446

7.  Desferrithiocin analogues and nephrotoxicity.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti; Shailendra Singh
Journal:  J Med Chem       Date:  2008-09-13       Impact factor: 7.446

8.  Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.

Authors:  Raymond J Bergeron; Jan Wiegand; Neelam Bharti; James S McManis
Journal:  J Med Chem       Date:  2012-08-13       Impact factor: 7.446

9.  Desferrithiocin analogue uranium decorporation agents.

Authors:  Raymond J Bergeron; Jan Wiegand; Shailendra Singh
Journal:  Int J Radiat Biol       Date:  2009-04       Impact factor: 2.694

10.  Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti; Shailendra Singh
Journal:  J Med Chem       Date:  2008-06-06       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.